About the T – emerge programclinical Roche T-emerge Phase III program is designed as a multicenter, multi-country, randomized, controlled , double-blind and open-label studies. 4 weeks.00 patients in eight studies that have been enrolled comprise the T – emerge program. The course consists of two parallel taspoglutide arms including 10 mg once weekly and 10 mg once weekly titrated up to 20 mg once weekly for 4 weeks. Four of the eight studies have active comparators, including exenatide, sitagliptin, insulin glargine and pioglitazone.

GLP-r Roche announces that Taspoglutide meets its primary endpoint in the first phase III trialIpsen , an innovative, global specialty pharmaceutical company, today announced that its partner Roche has announced the results of a first phase III clinical trial known taspoglutide, the first human once weekly glucagon-like peptide-1 analogue that. From Ipsen Research The results of Roche phase III study T-emerge 2 met its primary endpoint of change in HbA1c . Be superior to exenatide was demonstrated.The researchers used cells out of the fatty tissue about of abdominal tuck operations as well mouse muscle cells of cultivated for experiments links. Over six days a said test cells were treated with Liu at the 30mW/cm2 for short bursts of three or ten minutes. Tested them for the number of cells, metabolism , viable and for signs of damage to the cells.